溶瘤I型单纯疱疹病毒的研究进展  

The research progress on oncolytic herpes simplex virus type 1

作　　者：由鹏飞 韩金乐 叶祥忠 

机构地区：[1]北京万泰生物药业股份有限公司,北京102206

出　　处：《微生物学通报》2015年第9期1795-1801,共7页Microbiology China

摘　　要：溶瘤病毒(Oncolytic virus,OV)是可以靶向感染并杀伤肿瘤细胞的一类病毒,其中溶瘤I型单纯疱疹病毒(Oncolytic herpes simplex virus type 1,OHSV-1)是目前研究最多的溶瘤病毒之一,可通过多种策略进行构建,已有多种OHSV-1进入临床试验,大量结果显示其具有较好的安全性和有效性。本文主要介绍OHSV-1的分子生物学特性与优势、主要的开发及靶向性策略、各类OHSV-1的研究进展以及目前存在的问题等。Oncolytic virus （OV） is a class of antitumor agents that selectively infect and kill tumor cells while sparing normal cells. Among various oncolytic viruses, oncolytic herpes simplex virus type 1 （OHSV-1） is one of the most widely explored agents. OHSV-1 can be constructed through various strategies. It has been investigated in clinical trials for patients with many types of cancers. These clinical studies have shown the safety and efficacy of OHSV-1. This review briefly summarizes the molecular biologic characteristics and advantages of OHSV-1, the development and targeting strategies of OHSV-1, the progresses in research on various OHSV-1 and discusses the currently problems with OHSV-1 in cancer therapy.

关 键 词：I型单纯疱疹病毒 溶瘤病毒 肿瘤治疗 

分 类 号：R373[医药卫生—病原生物学]